A. Ruol

4.6k total citations · 2 hit papers
67 papers, 3.6k citations indexed

About

A. Ruol is a scholar working on Hepatology, Epidemiology and Pharmacology. According to data from OpenAlex, A. Ruol has authored 67 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hepatology, 45 papers in Epidemiology and 5 papers in Pharmacology. Recurrent topics in A. Ruol's work include Liver Disease Diagnosis and Treatment (34 papers), Hepatitis C virus research (28 papers) and Hepatitis B Virus Studies (24 papers). A. Ruol is often cited by papers focused on Liver Disease Diagnosis and Treatment (34 papers), Hepatitis C virus research (28 papers) and Hepatitis B Virus Studies (24 papers). A. Ruol collaborates with scholars based in Italy, Netherlands and Germany. A. Ruol's co-authors include A. Albertí, G. Giustina, Giovanna Fattovich, G. Realdi, Patrizia Pontisso, S. Favarato, F. Tremolada, Massimo Rugge, L. Brollo and A Rigoli and has published in prestigious journals such as The Lancet, Blood and Annals of Internal Medicine.

In The Last Decade

A. Ruol

65 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1992 468 citations Paolo Prandoni, Mariarosa Carta et al. The Lancet profile →
Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection

1980 377 citations G. Realdi, A. Albertí et al. profile →

Peers

Countries citing papers authored by A. Ruol

Since Specialization

Citations

This map shows the geographic impact of A. Ruol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Ruol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Ruol more than expected).

Fields of papers citing papers by A. Ruol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Ruol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Ruol. The network helps show where A. Ruol may publish in the future.

Co-authorship network of co-authors of A. Ruol

This figure shows the co-authorship network connecting the top 25 collaborators of A. Ruol. A scholar is included among the top collaborators of A. Ruol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Ruol. A. Ruol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Serum procollagen type III peptide in chronic hepatitis B 1996 ·International Journal of Clinical & Laboratory Research ·G. Giustina, Giovanna Fattovich, Massimo De Paoli, Maria Guido, S. Favarato, Massimo Rugge, A. Albertí, A. Ruol, Mario Plebani	12
2	[The side effects associated with the interferon-alpha therapy of chronic viral hepatitis]. 1995 ·PubMed ·Giovanna Fattovich, G. Giustina, S. Favarato, A. Ruol	1
3	Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2α 1994 ·Journal of Hepatology ·(unknown), G. Diodati, (unknown), C. Casarin, Sergio Scaccabarozzi, G. Realdi, A. Ruol, A. Albertí	42
4	A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B 1994 ·Journal of Hepatology ·Giovanna Fattovich, G. Giustina, A. Albertí, Maria Guido, Patrizia Pontisso, S. Favarato, Luisa Benvegnù, A. Ruol	11
5	Space‐occupying lesions of the liver detected by ultrasonography and their relation to hepatocellular carcinoma in cirrhosis 1992 ·Liver International ·Luisa Benvegnù, A. Cecchetto, F. Noventa, F. Tremolada, A. Ruol, A. Albertí	2
6	The preS1 domain of hepatitis B virus and IgA cross-react in their binding to the hepatocyte surface 1992 ·Journal of General Virology ·Patrizia Pontisso, Mariagrazia Ruvoletto, Claudio Tiribelli, Wolfram H. Gerlich, A. Ruol, A. Albertí	33
7	Interferon therapy of cryptogenic chronic active liver disease and its relationship to anti-HCV 1992 ·PubMed ·G. Diodati, (unknown), A. Tagger, A. Albertí, G. Realdi, A. Ruol	4
8	Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis breakdown → 1992 ·The Lancet ·Paolo Prandoni, Mariarosa Carta, Alberto Cogo, A. Ruol, Mario Vigo, Dario Casara, A.W.A. Lensing, H.R. Büller, J W ten Cate	468
9	Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV 1992 ·The Lancet ·A. Albertí, Giulia Morsica, Liliana Chemello, D. Cavalletto, Franco Noventa, Patrizia Pontisso, A. Ruol	331
10	Natural history and prognostic factors for chronic hepatitis type B. 1991 ·Gut ·Giovanna Fattovich, L. Brollo, G. Giustina, F. Noventa, Patrizia Pontisso, A. Albertí, G. Realdi, A. Ruol	330
11	Antibody to Hepatitis C Virus in Post-Transfusion Hepatitis 1991 ·Annals of Internal Medicine ·F. Tremolada, C. Casarin, A. Tagger, (unknown), G. Realdi, A. Albertí, A. Ruol	92
12	Antibody to hepatitis C virus in cryptogenic chronic liver disease 1991 ·Journal of Medical Virology ·G. Diodati, A. Tagger, Paola Bonetti, M.L. Ribero, (unknown), D. Cavalletto, (unknown), G. Realdi, A. Ruol, A. Albertí	12
13	Hepatitis C Virus Infection in Chronic Hepatitis B Virus Carriers 1991 ·The Journal of Infectious Diseases ·Giovanna Fattovich, A. Tagger, L. Brollo, G. Giustina, Patrizia Pontisso, G. Realdi, A. Albertí, A. Ruol	118
14	Antibody to Hepatitis C Virus and Liver Disease in Volunteer Blood Donors 1991 ·Annals of Internal Medicine ·A. Albertí, (unknown), (unknown), A. Tagger, Antonio Dal Canton, Nicola Bizzaro, Giuseppe Tagariello, A. Ruol	64
15	Treatment of Deep Venous Thrombosis by Fixed Doses of a Low-Molecular-Weight Heparin (CY216) 1990 ·Pathophysiology of Haemostasis and Thrombosis ·Paolo Prandoni, Mario Vigo, Anna Maria Cattelan, A. Ruol	35
16	Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B 1989 ·Journal of Hepatology ·Giovanna Fattovich, L. Brollo, (unknown), Patrizia Pontisso, G. Giustina, Domenico Criscuolo, (unknown), A. Albertí, G. Realdi, A. Ruol	37
17	Long‐term effects of beta‐adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics 1987 ·Clinical Physiology ·Angelo Gatta, Massimo Bolognesi, Carlo Merkel, G. F. Finucci, Paolo Angeli, David Sacerdoti, A. Ruol	7
18	Renal effects of nadolol in cirrhosis 1987 ·European Journal of Clinical Pharmacology ·Angelo Gatta, David Sacerdoti, Carlo Merkel, Lorenza Caregaro, (unknown), Massimo Bolognesi, A. Ruol	5
19	ß2-Microglobulin Concentration in Plasma and Production in Liver Cirrhosis 1984 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Piero Amodio, (unknown), A. Ruol	1
20	Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. 1982 ·Gut ·G. Realdi, A. Albertí, Massimo Rugge, A Rigoli, F. Tremolada, L Schivazappa, A. Ruol	158

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact